Gilead Sciences IncGILD:NSQ

70.00
0.72 / 1.04%
17.55m
34.77%
0.6626
Close in USDToday's changeShares traded1 year changeBeta
As of Apr 17 2014 21:00 BST.Data delayed by at least 15 minutes.

Consensus recommendation

As of Apr 12, 2014, the consensus forecast amongst 32 polled investment analysts covering Gilead Sciences, Inc. advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Oct 21, 2009. The previous consensus forecast advised investors to purchase equity in Gilead Sciences, Inc..

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
Buy13
Outperform11
Hold7
Underperform0
Sell0
No opinion0

Research Reports

Ford Investor Services, Inc.
S&P Capital IQ – STARS Reports
MarketLine (a Datamonitor Company)

Share price forecast

The 24 analysts offering 12 month price targets for Gilead Sciences, Inc. have a median target of 97.50, with a high estimate of 132.00 and a low estimate of 63.00. The median estimate represents a 39.29% increase from the last price of 70.00. View Full Financials

High+88.6 %132.00
Med+39.3 %97.50
Low-10.0 %63.00

Dividends

Dividend information is not available for Gilead Sciences Inc. View Full Financials

Earnings history & estimates

On Feb 04, 2014, Gilead Sciences, Inc. reported 4th quarter 2013 earnings of 0.550 per share. This result exceeded the 0.50 consensus of the 28 analysts covering the company and exceeded last year's 4th quarter results by 10.00%.
The next earnings announcement is expected on Apr 22, 2014. View Full Interim Financials

Average growth rate+2.48 %

Gilead Sciences, Inc. reported annual 2013 earnings of 2.04 per share on Feb 04, 2014. View Full Annual Financials

Average growth rate+10.28 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement

Revenue

Gilead Sciences Inc. had 4th quarter 2013 revenues of 3.12bn. This bettered the 2.86bn consensus of the 26 analysts covering the company. This was 12.11% above the prior year's 4th quarter results. View Full Interim Financials

Average growth rate+4.95 %

Gilead Sciences Inc. had revenues for the full year 2013 of 11.20bn. This was 15.45% above the prior year's results. View Full Annual Financials

Average growth rate+12.51 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.